Absolute Antibody is a privately funded startup company developing engineered antibodies for the research and diagnostics markets.
We have developed a proprietary manufacturing platform based on transient transfection for the production of sequenced and engineered antibodies, AbsoluteAbs (AbAbs). The manufacture of AbAbs is fast, inexpensive and animal-free, with 100s of mgs produced within two weeks, versus up to three months required by traditional methods, enabling Absolute Antibody to offer vastly reduced time from order to delivery.
Antibody sequencing, manufacturing and engineering services are offered to all antibody users but we are also developing a catalog of engineered antibodies. They provide a number of benefits over antibodies produced using traditional methods, including ultra-low batch-to-batch variability leading to improved reproducibility of results, and the ability to eliminate undesirable properties or add desirable features. For example, the binding potential for complement and Fc receptors can be eliminated to minimise background staining and provide cleaner results, while desirable features such as tags for detection and purification can be built into the AbAbs.